Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-07 DOI:10.1080/14796694.2025.2554354

Bijal D Shah, Mei Xue, Wesley Furnback, Keri Yang

{"title":"Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.","authors":"Bijal D Shah, Mei Xue, Wesley Furnback, Keri Yang","doi":"10.1080/14796694.2025.2554354","DOIUrl":null,"url":null,"abstract":"Aims: This study examines United States real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns, duration, and adherence in mantle cell lymphoma (MCL) patients.Materials & methods: A retrospective analysis of electronic medical records for patients with MCL who initiated a BTKi between January 2019 and November 2021 was conducted. Patients were followed ≥ 6 months, examining baseline characteristics and outcomes including treatment duration and adherence.Results: 402 patients initiated acalabrutinib (n = 161), ibrutinib (n = 197), or zanubrutinib (n = 44). The zanubrutinib group demonstrated significantly longer median treatment duration (292 days) compared with acalabrutinib (259 days) and ibrutinib (149 days; P < 0.01) and displayed significantly higher adherence to treatment.Conclusions: In this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3043-3049"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490371/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2554354","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: This study examines United States real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns, duration, and adherence in mantle cell lymphoma (MCL) patients.

Materials & methods: A retrospective analysis of electronic medical records for patients with MCL who initiated a BTKi between January 2019 and November 2021 was conducted. Patients were followed ≥ 6 months, examining baseline characteristics and outcomes including treatment duration and adherence.

Results: 402 patients initiated acalabrutinib (n = 161), ibrutinib (n = 197), or zanubrutinib (n = 44). The zanubrutinib group demonstrated significantly longer median treatment duration (292 days) compared with acalabrutinib (259 days) and ibrutinib (149 days; P < 0.01) and displayed significantly higher adherence to treatment.

Conclusions: In this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.

Abstract Image

查看原文本刊更多论文

布鲁顿酪氨酸激酶抑制剂治疗套细胞淋巴瘤的现实世界治疗模式在社区肿瘤学设置。

目的：本研究探讨了美国布鲁顿酪氨酸激酶抑制剂（BTKi）在套细胞淋巴瘤（MCL）患者中的治疗模式、持续时间和依从性。材料与方法：回顾性分析2019年1月至2021年11月期间启动BTKi的MCL患者的电子病历。患者随访≥6个月，检查基线特征和结果，包括治疗持续时间和依从性。结果：402例患者开始使用阿卡拉布替尼（n = 161）、伊布鲁替尼（n = 197）或扎努布鲁替尼（n = 44）。与阿卡拉布替尼（259天）和伊鲁替尼（149天）相比，zanubrutinib组的中位治疗持续时间（292天）明显更长；P结论：在本研究中，与阿卡拉布替尼和伊鲁替尼组相比，zanubrutinib组的治疗持续时间明显更长，依从性更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.